Ipilimumab versus placebo after radiotherapy in patients with metastatic castration-resistant prostate cancer that had progressed after docetaxel chemotherapy …
Background Ipilimumab is a fully human monoclonal antibody that binds cytotoxic T-lymphocyte
antigen 4 to enhance antitumour immunity. Our aim was to assess the use of ipilimumab …
antigen 4 to enhance antitumour immunity. Our aim was to assess the use of ipilimumab …
Cabozantinib versus everolimus in advanced renal cell carcinoma (METEOR): final results from a randomised, open-label, phase 3 trial
Background Cabozantinib is an oral inhibitor of tyrosine kinases including MET, VEGFR,
and AXL. The randomised phase 3 METEOR trial compared the efficacy and safety of …
and AXL. The randomised phase 3 METEOR trial compared the efficacy and safety of …
[HTML][HTML] Survival with olaparib in metastatic castration-resistant prostate cancer
Background We previously reported that olaparib led to significantly longer imaging-based
progression-free survival than the physician’s choice of enzalutamide or abiraterone among …
progression-free survival than the physician’s choice of enzalutamide or abiraterone among …
Functional heterogeneity of mutant rhodopsins responsible for autosomal dominant retinitis pigmentosa.
CH Sung, BG Schneider, N Agarwal… - Proceedings of the …, 1991 - National Acad Sciences
Thirteen mutant rhodopsins responsible for autosomal dominant retinitis pigmentosa (ADRP)
have been produced by transfection of cloned cDNA into tissue culture cells. Three mutants …
have been produced by transfection of cloned cDNA into tissue culture cells. Three mutants …
[HTML][HTML] Apalutamide for metastatic, castration-sensitive prostate cancer
Background Apalutamide is an inhibitor of the ligand-binding domain of the androgen
receptor. Whether the addition of apalutamide to androgen-deprivation therapy (ADT) would …
receptor. Whether the addition of apalutamide to androgen-deprivation therapy (ADT) would …
Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study
Background Data on patients with COVID-19 who have cancer are lacking. Here we characterise
the outcomes of a cohort of patients with cancer and COVID-19 and identify potential …
the outcomes of a cohort of patients with cancer and COVID-19 and identify potential …
[HTML][HTML] Olaparib for metastatic castration-resistant prostate cancer
Background Multiple loss-of-function alterations in genes that are involved in DNA repair,
including homologous recombination repair, are associated with response to poly(adenosine …
including homologous recombination repair, are associated with response to poly(adenosine …
Kidney cancer, version 3.2022, NCCN clinical practice guidelines in oncology
The NCCN Guidelines for Kidney Cancer focus on the screening, diagnosis, staging, treatment,
and management of renal cell carcinoma (RCC). Patients with relapsed or stage IV RCC …
and management of renal cell carcinoma (RCC). Patients with relapsed or stage IV RCC …
Clinical cancer advances 2019: annual report on progress against cancer from the American society of clinical oncology
… Miller, Neeraj Agarwal, Susan Marina Chang, Mariana Chavez-MacGregor, Ezra Cohen,
Suzanne Cole, William Dale, Catherine S.Magid Diefenbach, Mary L. Disis, Robert Dreicer …
Suzanne Cole, William Dale, Catherine S.Magid Diefenbach, Mary L. Disis, Robert Dreicer …
External validation and comparison with other models of the International Metastatic Renal-Cell Carcinoma Database Consortium prognostic model: a population …
Background The International Metastatic Renal-Cell Carcinoma Database Consortium model
offers prognostic information for patients with metastatic renal-cell carcinoma. We tested …
offers prognostic information for patients with metastatic renal-cell carcinoma. We tested …